Valuation: Genmab

Market Cap 106B 16.12B 14.12B 13.03B 12.17B 22.91B 1,524B 23.43B 157B 60.55B 752B 60.55B 59.22B 2,611B P/E 2026 *
22.6x
P/E 2027 * 15.8x
Enterprise Value 125B 19.1B 16.73B 15.44B 14.42B 27.14B 1,806B 27.76B 186B 71.73B 891B 71.74B 70.16B 3,093B EV / Sales 2026 *
4.51x
EV / Sales 2027 * 3.64x
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 15.94B
+0.13%+1.50%+63.86%+123.95% 55.63B
+6.76%+22.83%+91.66%+101.42% 52.25B
+3.33%+3.71%-11.68%-11.82% 23.07B
+1.32%+9.33%+5.28%+419.80% 22.41B
+6.78%+14.47%+40.28%-6.67% 17.32B
-0.89%+4.57%+24.30%+185.83% 13.77B
+9.96%+19.81%+157.65%+320.70% 13.47B
+4.21%+4.76%+33.21% - 12.43B
+2.85%+4.26%+75.32%+137.86% 11.82B
Average +3.30%+6.54%+53.32%+158.88% 24.68B
Weighted average by Cap. +3.24%+7.54%+56.94%+141.70%

Financials

2026 *2027 *
Net sales 27.69B 4.23B 3.71B 3.42B 3.19B 6.01B 400B 6.15B 41.17B 15.89B 197B 15.89B 15.54B 685B 32.41B 4.95B 4.34B 4B 3.74B 7.04B 468B 7.2B 48.18B 18.6B 231B 18.6B 18.19B 802B
Net income 4.76B 727M 636M 587M 549M 1.03B 68.71B 1.06B 7.07B 2.73B 33.9B 2.73B 2.67B 118B 7.02B 1.07B 939M 867M 810M 1.52B 101B 1.56B 10.44B 4.03B 50.04B 4.03B 3.94B 174B
Net Debt 19.49B 2.98B 2.61B 2.41B 2.25B 4.23B 282B 4.33B 28.97B 11.18B 139B 11.18B 10.94B 482B 12.47B 1.91B 1.67B 1.54B 1.44B 2.71B 180B 2.77B 18.54B 7.16B 88.89B 7.16B 7B 309B
Logo Genmab
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A